Literature DB >> 3148816

Cytidine 5'-monophospho-N-acetyl neuraminic acid and a low molecular weight factor from human blood cells induce lipopolysaccharide alteration in gonococci when conferring resistance to killing by human serum.

N J Parsons1, P V Patel, E L Tan, J R Andrade, C A Nairn, M Goldner, J A Cole, H Smith.   

Abstract

Recently evidence has been obtained that a minute amount of cytidine 5'-monophospho-N-acetyl neuraminic acid (CMP-NANA) or a closely related compound is the low Mr factor in human red blood cells which induces Neisseria gonorrhoeae (BS4(agar] to resistance to killing by fresh human serum. Induction of gonococci to resistance by both CMP-NANA and semi-purified low Mr factor from red blood cells was accompanied by a 35-55% reduction of silver staining of lipopolysaccharide separated in SDS-PAGE gels of proteinase K digests. These alterations in lipopolysaccharide are probably responsible for conferring serum resistance. However, lipopolysaccharide-containing digests from resistant as well as from susceptible gonococci neutralised serum bactericidal activity. These observations may have wider implications since CMP-NANA is a sialylating agent wide-spread in mammalian tissues and LPS is ubiquitous amongst Gram-negative pathogens.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3148816     DOI: 10.1016/0882-4010(88)90103-9

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  51 in total

1.  An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae.

Authors:  Sarika Agarwal; Viviana P Ferreira; Claudio Cortes; Michael K Pangburn; Peter A Rice; Sanjay Ram
Journal:  J Immunol       Date:  2010-06-07       Impact factor: 5.422

2.  Effect of exogenous sialylation of the lipooligosaccharide of Neisseria gonorrhoeae on opsonophagocytosis.

Authors:  J J Kim; D Zhou; R E Mandrell; J M Griffiss
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

3.  Gonococci in vivo: Host CMP-NANA, sialylated lipopolysaccharide and serum resistance.

Authors:  H Smith
Journal:  Can J Infect Dis       Date:  1993-01

Review 4.  Host Sialic Acids: A Delicacy for the Pathogen with Discerning Taste.

Authors:  Brandy L Haines-Menges; W Brian Whitaker; J B Lubin; E Fidelma Boyd
Journal:  Microbiol Spectr       Date:  2015-08

5.  Enhanced factor H binding to sialylated Gonococci is restricted to the sialylated lacto-N-neotetraose lipooligosaccharide species: implications for serum resistance and evidence for a bifunctional lipooligosaccharide sialyltransferase in Gonococci.

Authors:  Sunita Gulati; Andrew Cox; Lisa A Lewis; Frank St Michael; Jianjun Li; Ryan Boden; Sanjay Ram; Peter A Rice
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

Review 6.  Mucosal infection with Neisseria gonorrhoeae. Bacterial adaptation and mucosal defenses.

Authors:  M S Cohen; P F Sparling
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

7.  Gonococcal lipooligosaccharide sialylation prevents complement-dependent killing by immune sera.

Authors:  L M Wetzler; K Barry; M S Blake; E C Gotschlich
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

8.  Uptake of Sialic Acid by Nontypeable Haemophilus influenzae Increases Complement Resistance through Decreasing IgM-Dependent Complement Activation.

Authors:  Marjolein M P Oerlemans; Sam J Moons; Jurriaan J A Heming; Thomas J Boltje; Marien I de Jonge; Jeroen D Langereis
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

Review 9.  The molecular mechanisms used by Neisseria gonorrhoeae to initiate infection differ between men and women.

Authors:  Jennifer L Edwards; Michael A Apicella
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

10.  Use of pyocin to select a Haemophilus ducreyi variant defective in lipooligosaccharide biosynthesis.

Authors:  A A Campagnari; R Karalus; M Apicella; W Melaugh; A J Lesse; B W Gibson
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.